Today Silvacx started at University of Heidelberg  (1 April 2023)

On April 1st 2023 the EXIST project Silvacx started at Heidelberg University. Our new location with office and lab is now at Im Neuenheimer Feld 329.

Silvacx receives EXIST I funding  (16 December 2022)

Today we got the official confirmation that Silvacx will receive an EXIST Transfer of Research grant from the Federal Ministry for Economic Affairs and Climate Action of Germany. The planned project start is on 1 March 2023 and the funding period is 30 months. It will be carried out at the Institute of Pharmacy and Molecular Biotechnology at Heidelberg University. Professor Gert Fricker is our mentor.
Our successful pitch was on 17 November 2022 in Berlin.

Silvacx heads BMBF founded R&D program MUNAVAC (1 February 2021)

Today the BMBF founded program MUNAVAC started. MUNAVAC is an acronym für "mucosal nanoparticulate vaccination". The R&D consortium is formed by the following partners:

  • Silvacx - as a project of Life Science Inkubator - is the consortium leader.
  • DKFZ Heidelberg, the German cancer research center
  • University Hospital Heidelberg
  • University of Heidelberg

The aim of the project is the development of a novel vaccine platform for needleless mucosal vaccination. Silvacx silica nanoparticles are an integral part of this project. Project duration is 2 years.

Silvacx Team in the local press (30 April 2020)

"Bensheimer entwickeln Impfplattform"

Rolf Brockmeyer joined the Silvacx Team too (1 February 2020)

Rolf Brockmeyer strengthens the Silvacx Team with his extraordinary expertise in Regulartory Affairs. Rolf has a PhD in pharmacy and worked for decades a Bayer AG. Welcome to the team!

Thomas Kessler joined the Silvacx Team (1 Januar 2020)

Today Thomas Kessler has officially joined the Silvacx Team. He takes care of business development, marketing and investor relations. With his complementary knowledge (chemistry and business administration) he understands both "worlds" very well. Welcome and enjoy our journey!

Silvacx is one of eight finalists of the BioRiver Boost! 2019 (4 October 2019)

Silvacx has been selected as one of eight finalists of the BioRiver Boost! 2019. We'll give a pitch presentation on 15 October 2019 at Miltenyi Biotec, Bergisch Gladbach. More information about this event can be found here.

Take the opportuity and meet us in Bergisch Gladbach!

Life Science Inkubator (LSI) Bonn for the first time supports pharma industry spin-out  (1 February 2018)

Merck spin-off Silvacx receives seed financing of almost EUR 2 million

Bonn, Germany, February 1, 2018 -- Life Science Inkubator GmbH (LSI) for the first time supports a research project originating from a pharma company. The project called Silvacx is a spin-off from Merck AG and is developing novel delivery technologies for cancer immunotherapy. The Silvacx team headed by Armin Kuebelbeck (previously Merck KGaA) also received public funding totaling EUR 1.93 million from the state of North Rhine-Westphalia´s Ministry of Culture and Science, which will be dedicated to further research and development activities over the next three years. Subsequently, clinical evaluation of the platform technology is planned.

The Silvacx technology licensed from Merck is based on silicon dioxide nanoparticles, which will be used as...

read the full article